Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice.
about
First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activityAdoptive T cell therapy for cancer in the clinicA randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancerDoxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma modelCancer immunotherapy: the beginning of the end of cancer?Concepts and mechanisms underlying chemotherapy induced immunogenic cell death: impact on clinical studies and considerations for combined therapiesRelevance of tumor-infiltrating lymphocytes in breast cancerVaccines for pancreatic cancerTherapeutic cancer vaccines: past, present, and futureCancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advancesAn update on vaccine therapy and other immunotherapeutic approaches for glioblastomaThe interplay of immunotherapy and chemotherapy: harnessing potential synergiesChemotherapeutics and radiation stimulate MHC class I expression through elevated interferon-beta signaling in breast cancer cellsTrafficking of high avidity HER-2/neu-specific T cells into HER-2/neu-expressing tumors after depletion of effector/memory-like regulatory T cellsCancer immunotherapy comes of ageRandomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccineIncreased immunogenicity of surviving tumor cells enables cooperation between liposomal doxorubicin and IL-18.Predicting environmental chemical factors associated with disease-related gene expression dataImmunological factors relating to the antitumor effect of temozolomide chemoimmunotherapy in a murine glioma model.The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy.Vaccines against human carcinomas: strategies to improve antitumor immune responses.In vivo cyclophosphamide and IL-2 treatment impedes self-antigen-induced effector CD4 cell tolerization: implications for adoptive immunotherapy.Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in miceBreathing new life into immunotherapy: review of melanoma, lung and kidney cancerLow-dose cyclophosphamide synergizes with dendritic cell-based immunotherapy in antitumor activity.Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs.Differential influence of anticancer treatments and angiogenesis on the seric titer of autoantibody used as tumor and metastasis biomarker.Combining low-dose cyclophosphamide with GM-CSF-secreting prostate cancer immunotherapy enhances antitumor immune effectsChemoimmunotherapy.The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunityAldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamideA strategy of tumor treatment in mice with doxorubicin-cyclophosphamide combination based on dendritic cell activation by human double-stranded DNA preparation.Chemotherapy delivered after viral immunogene therapy augments antitumor efficacy via multiple immune-mediated mechanismsThe role of immunotherapy in solid tumors: report from the Campania Society of Oncology Immunotherapy (SCITO) meeting, Naples 2014A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancer.PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors.Pretreatment with cisplatin enhances E7-specific CD8+ T-Cell-mediated antitumor immunity induced by DNA vaccination.Immunotherapy for ovarian cancer: what's next?Enhancement of CD4+ T-cell help reverses the doxorubicin-induced suppression of antigen-specific immune responses in vaccinated miceThe combination of a low-dose chemotherapeutic agent, 5-fluorouracil, and an adenoviral tumor vaccine has a synergistic benefit on survival in a tumor model system.
P2860
Q21245463-E3915B52-9FF3-4192-9E6E-D24007762A50Q24680405-D1C4FAAD-1540-4859-8A9A-310A0EB651A5Q24684241-D35E4985-0E63-4F14-B85C-D38C9A66C87CQ24805875-C3360963-8B19-4608-A1C4-C1729FF7744CQ26752277-0C72F564-E4BD-4010-8AEA-57ACC14467C7Q26781215-6A5CA641-82C0-462A-BFAD-53BDF90B8F8EQ26795598-0C9F9028-EA04-4290-9692-269B0BF7D7CBQ26825850-B4F121D5-DB9F-4401-84DA-EB784AE2CFDDQ26863283-512F8DF5-8DB0-492E-B4E8-B6BBC13E725DQ26863779-95C384BE-906B-46CC-A7E3-0E6A175CF136Q27024830-C39567D1-748F-4E35-8B46-C7CD29D77437Q28081893-CD89D99B-7C2D-48CB-8158-922D257F66F1Q28481351-97A4855E-FEE2-4632-B5D9-B17FAEDDFB9DQ28732041-1920DA6E-5D81-49BB-B9C9-648B544DA406Q29619918-6432B04B-515E-4564-BAD5-E32AB4FD80A0Q30425914-E3E9B9BA-D8FF-4009-973E-201607B77F0DQ33552702-0093B48C-8A4E-4310-9E63-1D437E5E6553Q33575070-E1E99205-DDC6-4118-B90C-E3F538D5B10EQ33613430-41D5D15A-821D-432E-B67A-7C97B946557BQ33660069-1DF12E8C-BEB9-491C-A34E-925A8D488DA0Q33734281-39A89B85-CAC5-43B1-AA30-B902B2E7EE09Q33756565-A8001575-44E2-435D-9D8B-A8A29F72EFA1Q33823499-27F03E49-7F06-48D8-AE58-D0F9DA8D4635Q33862861-9A078771-36E2-4DF0-B2FF-AB1B19679279Q33871059-3045AB86-40CA-4F38-9CE3-AC1A93113D5EQ33896713-6DC1D7BD-6555-49F3-8673-CAC593C3F1E0Q34009845-B1F69C62-E2BB-4CCC-972B-60F7D630FECBQ34013869-F800C066-D33D-4A7F-B392-477296F9F4C0Q34058792-B3D10127-D96D-4AB5-BA06-0AC7FE167C6DQ34073138-4BE75E71-1F17-45E9-965C-7A50531062B3Q34138598-2D811B02-C8DD-4DC9-8A81-2FDE638B5C41Q34330865-2334F195-59F4-40D8-8299-A2DDB6AC8124Q34343736-F0B421CE-CC80-4108-8D16-185D0BB86F79Q34402325-0034B9A8-8081-416B-AB1A-9A53B2EE2164Q34412289-4E0F128E-D4AD-4B50-9390-6F1C52E158FCQ34644359-B4127DEC-2E8B-4BC9-8D55-DEF1E21B2B07Q34732544-BD9764A9-2857-4CC2-9168-CC78ECDC87BAQ34743514-25A571B2-3B64-4921-AE1F-F3B526EB1A26Q34766642-3342C760-E414-4615-9304-9E5B9BB3DA97Q34808155-5FB40963-F148-4E73-BE95-E9903B22800A
P2860
Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
2001年论文
@zh
2001年论文
@zh-cn
name
Cyclophosphamide, doxorubicin, ...... s in HER-2/neu tolerized mice.
@en
Cyclophosphamide, doxorubicin, ...... s in HER-2/neu tolerized mice.
@nl
type
label
Cyclophosphamide, doxorubicin, ...... s in HER-2/neu tolerized mice.
@en
Cyclophosphamide, doxorubicin, ...... s in HER-2/neu tolerized mice.
@nl
prefLabel
Cyclophosphamide, doxorubicin, ...... s in HER-2/neu tolerized mice.
@en
Cyclophosphamide, doxorubicin, ...... s in HER-2/neu tolerized mice.
@nl
P2093
P1433
P1476
Cyclophosphamide, doxorubicin, ...... es in HER-2/neu tolerized mice
@en
P2093
Ercolini AM
Machiels JP
Weintraub D
P304
P407
P577
2001-05-01T00:00:00Z